A randomised trial of weekly cetuximab and radiation versus weekly cisplatin and radiation in good prognosis loco regionally advanced HPV-associated oropharyngeal squamous cell carcinoma

The excellent prognosis of patients with low-risk human papillomavirus (HPV)- associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiation therapy and cisplatin, leading to interest in de-intensification trials. We investigated whether cetuximab, an epidermal growth factor receptor targeting antibody, when combined with radiation therapy would result in a decrease in symptom burden and toxicity with similar efficacy compared with weekly cisplatin.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

189

Closing Date of Accrual

7 June 2018

Trial Chairperson

Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC, Australia

A/Prof June Corry, GenesisCare St Vincents, NSW, Australia

Trial Contact

Annie.Ko@petermac.org

Clinical Trial Registration

Related Post

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research
27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

LATEST NEWS: 27 May 2025 A team of five

Clinical Trials Day 2025 stand at Calvary Mater Newcastle
27 May, 2025

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff